Asarina Pharma Proposals regarding the Board of Directors for the Annual General Meeting 2019

(April 11 2019) The following proposals (items 12-15 in the agenda) for the upcoming Annual General Meeting have been made:

-        Number of directors: six (6)

-        Annual remuneration to the Board of Directors: SEK 500,000 to the Chairman of the Board and SEK 200,000 to each of the other independent directors,

-        Election of directors: re-election of Paul de Potocki, Marianne Kock, Miroslav Reljanovic and André Ulmann and election of Mathieu Simon and Vidar Wendal-Hansen; it is noted that Thierry Laugel and Ola Flink have declined to be re-elected, and

-        Chairman of the Board: re-election of Paul de Potocki.

Mathieu Simon is born 1956 and has a MD from Faculty of Medicine, Paris VII. He is today Senior Advisor at Messier Maris & Associés, an advisory M&A firm located in Paris, New York and London. In addition to this role, Mathieu is a Venture partner at B/B biotec Pureos Bioventures (Bellevue Venture Capital) (CH), an independent director of the Board of Vaximm AG (CH) and a member of the Supervisory Board of Affimed (AFMD) (NASDAQ). Mathieu is also advisor at the EU Commission (Horizon 2020 Programme). He has extensive experience from international pharmaceutical companies, inter alia as part of the management of Cellectis SA, Pierre Fabre SA, Ectycell and Wyeth Pharmaceuticals. He has also served as chairman of Cellartis AB and as board member Cellectis. Mathieu is independent in relation to the company and the company's major shareholders. He does not own any shares or other financial instruments in Asarina Pharma.

Vidar Wendal-Hansen is born 1959 and has a MD, PhD from Karolinska Institutet. Vidar has more than 20 years of experience from preclinical and clinical drug development. He has worked as a medical director in both small biotechnology companies and large pharmaceutical companies, including Gilead Sciences and Novartis. Vidar has also worked as a clinical assessor at the Swedish Medical Products Agency. Vidar is independent in relation to the company and the company's major shareholders. He does not own any shares or other financial instruments in Asarina Pharma.

For further information, please contact:

Peter Nordkild, CEO, Asarina Pharma AB

Phone: +45 25 47 16 46

E-mail: peter.nordkild@asarinapharma.com

Jakob Dynnes Hansen, CFO, Asarina Pharma AB

Phone: +45 5132 3698

E-mail: jakob.dynnes@asarinapharma.com

About Asarina Pharma

We are a Swedish biotech company developing Sepranolone, the world’s first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Our product pipeline is built on over 40 years’ research into menstrual-related disorders like PMDD and menstrual migraine. With our new family of GAMSA compounds (GABAAModulating Steroid Antagonists), we aim to deliver a new generation of efficacious and safe drugs for still widely untreated conditions, thereby becoming a leading Women’s Health company.

Tags:

Subscribe

Documents & Links